New hope for Tough-to-Treat colon cancer: experimental drug combo enters human testing
Disease control
ENROLLING_BY_INVITATION
This study is testing whether adding an experimental drug called XS-03 to standard chemotherapy combinations helps control metastatic colorectal cancer that has a specific genetic change called a RAS mutation. The trial will first find the safest dose of XS-03, then see if the ne…
Phase: PHASE1, PHASE2 • Sponsor: NovaOnco Therapeutics Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC